高危单胎妊娠妇女预防自发性早产的干预措施:系统评价与网状Meta分析
该系统评价与网状Meta分析共纳入61项随机对照试验、17 273名孕妇,比较卧床休息、宫颈环扎、宫颈托、鱼油、营养补充、孕酮、抗生素、宫缩抑制剂等预防自发性早产的效果。以安慰剂或不治疗为对照,阴道孕酮与<34周早产减少相关(OR 0.50,95%CrI 0.34–0.70,高确定性证据),且是唯一对围产期死亡显示明确益处的治疗(OR 0.66,95%CrI 0.44–0.97,中等确定性证据)。仅孕酮治疗与新生儿呼吸窘迫综合征、新生儿败血症、坏死性小肠结肠炎及新生儿重症监护室入院减少相关。作者认为阴道孕酮应被视为这类高危妇女的首选预防治疗。
要点
- 对有自发性早产史或宫颈短的单胎妊娠妇女,阴道孕酮减少<34周早产(OR 0.50,95%CrI 0.34–0.70,高确定性证据)。
- 阴道孕酮是唯一对围产期死亡显示明确益处的治疗(OR 0.66,95%CrI 0.44–0.97,中等确定性证据)。
- Shirodkar宫颈环扎效应量最大(OR 0.06,95%CrI 0.00–0.84),但证据确定性低。
- 17OHPC(OR 0.68,95%CrI 0.43–1.02)、宫颈托(OR 0.65,95%CrI 0.39–1.08)、鱼油或omega 3(OR 0.30,95%CrI 0.06–1.23)可能减少<34周早产,均为中等确定性证据。
- 仅孕酮治疗与新生儿呼吸窘迫综合征、新生儿败血症、坏死性小肠结肠炎及新生儿重症监护室入院减少相关。
适用人群与场景
- 因有自发性早产史或宫颈短而处于自发性早产高风险的孕妇。
- 纳入标准:随机对照试验的孕妇,高风险定义为有自发性早产史或宫颈短。
- 研究限于单胎妊娠。
处置流程与药物剂量
- 以安慰剂或不治疗为对照,阴道孕酮与<34周早产减少相关(OR 0.50,95%CrI 0.34–0.70,高确定性证据)。
- 以安慰剂或不治疗为对照,阴道孕酮与围产期死亡减少相关(OR 0.66,95%CrI 0.44–0.97,中等确定性证据)。
- Shirodkar宫颈环扎与<34周早产减少相关(OR 0.06,95%CrI 0.00–0.84),证据确定性低。
- 17OHPC可能与<34周早产减少相关(OR 0.68,95%CrI 0.43–1.02,中等确定性证据)。
- 宫颈托可能与<34周早产减少相关(OR 0.65,95%CrI 0.39–1.08,中等确定性证据)。
- 鱼油或omega 3可能与<34周早产减少相关(OR 0.30,95%CrI 0.06–1.23,中等确定性证据)。
- 17OHPC(OR 0.78,95%CrI 0.50–1.21)、McDonald宫颈环扎(OR 0.59,95%CrI 0.33–1.03)、未指明类型的宫颈环扎(OR 0.77,95%CrI 0.53–1.11)可能降低围产期死亡,但可信区间不能排除伤害的可能性(均为中等确定性证据)。
研究设计与关键结果
- 研究设计:系统评价与贝叶斯网状Meta分析,共纳入61项随机对照试验、17 273名孕妇,至少贡献一个结局的数据。
- <34周早产分析纳入40项试验、13 310名孕妇;围产期死亡分析纳入30项试验、12 119名孕妇。
- 以安慰剂或不治疗为对照,阴道孕酮减少<34周早产(OR 0.50,95%CrI 0.34–0.70,高确定性证据)。
- Shirodkar宫颈环扎效应量最大(OR 0.06,95%CrI 0.00–0.84),但证据确定性低。
- 17OHPC(OR 0.68,95%CrI 0.43–1.02,中等确定性)、宫颈托(OR 0.65,95%CrI 0.39–1.08,中等确定性)、鱼油或omega 3(OR 0.30,95%CrI 0.06–1.23,中等确定性)可能减少<34周早产。
- 围产期死亡:阴道孕酮是唯一显示明确益处的治疗(OR 0.66,95%CrI 0.44–0.97,中等确定性)。
- 17OHPC(OR 0.78,95%CrI 0.50–1.21)、McDonald宫颈环扎(OR 0.59,95%CrI 0.33–1.03)、未指明类型的宫颈环扎(OR 0.77,95%CrI 0.53–1.11)可能降低围产期死亡,但可信区间不能排除伤害的可能性(均为中等确定性证据)。
- 仅孕酮治疗与新生儿呼吸窘迫综合征、新生儿败血症、坏死性小肠结肠炎及新生儿重症监护室入院减少相关(与对照相比)。
证据类型、等级与局限
- 证据类型:系统评价与贝叶斯网状Meta分析,纳入随机对照试验。
- 证据确定性:阴道孕酮减少<34周早产为高确定性;阴道孕酮减少围产期死亡、17OHPC、宫颈托、鱼油或omega 3减少<34周早产、17OHPC/McDonald宫颈环扎/未指明类型宫颈环扎减少围产期死亡均为中等确定性;Shirodkar宫颈环扎为低确定性。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,对于因有自发性早产史或宫颈短而被识别为有自发性早产风险的单胎妊娠妇女,阴道孕酮应被视为首选预防治疗。
- 作者建议,未来的随机对照试验应使用阴道孕酮作为对照,以识别更好的治疗或联合治疗。
指南或共识出处
- 系统评价注册号:PROSPERO CRD42020169006。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To compare the efficacy of bed rest, cervical cerclage (McDonald, Shirodkar, or unspecified type of cerclage), cervical pessary, fish oils or omega fatty acids, nutritional supplements (zinc), progesterone (intramuscular, oral, or vaginal), prophylactic antibiotics, prophylactic tocolytics, combinations of interventions, placebo or no treatment (control) to prevent spontaneous preterm birth in women with a singleton pregnancy and a history of spontaneous preterm birth or short cervical length.
DESIGN: Systematic review with bayesian network meta-analysis.
DATA SOURCES: The Cochrane Pregnancy and Childbirth Group's Database of Trials, the Cochrane Central Register of Controlled Trials, Medline, Embase, CINAHL, relevant journals, conference proceedings, and registries of ongoing trials.
ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Randomised controlled trials of pregnant women who are at high risk of spontaneous preterm birth because of a history of spontaneous preterm birth or short cervical length. No language or date restrictions were applied.
OUTCOMES: Seven maternal outcomes and 11 fetal outcomes were analysed in line with published core outcomes for preterm birth research. Relative treatment effects (odds ratios and 95% credible intervals) and certainty of evidence are presented for outcomes of preterm birth <34 weeks and perinatal death.
RESULTS: Sixty one trials (17 273 pregnant women) contributed data for the analysis of at least one outcome. For preterm birth <34 weeks (40 trials, 13 310 pregnant women) and with placebo or no treatment as the comparator, vaginal progesterone was associated with fewer women with preterm birth <34 weeks (odds ratio 0.50, 95% credible interval 0.34 to 0.70, high certainty of evidence). Shirodkar cerclage showed the largest effect size (0.06, 0.00 to 0.84), but the certainty of evidence was low. 17OHPC (17α-hydroxyprogesterone caproate; 0.68, 0.43 to 1.02, moderate certainty), vaginal pessary (0.65, 0.39 to 1.08, moderate certainty), and fish oil or omega 3 (0.30, 0.06 to 1.23, moderate certainty) might also reduce preterm birth <34 weeks compared with placebo or no treatment. For the fetal outcome of perinatal death (30 trials, 12 119 pregnant women) and with placebo or no treatment as the comparator, vaginal progesterone was the only treatment that showed clear evidence of benefit for this outcome (0.66, 0.44 to 0.97, moderate certainty). 17OHPC (0.78, 0.50 to 1.21, moderate certainty), McDonald cerclage (0.59, 0.33 to 1.03, moderate certainty), and unspecified cerclage (0.77, 0.53 to 1.11, moderate certainty) might reduce perinatal death rates, but credible intervals could not exclude the possibility of harm. Only progesterone treatments are associated with reduction in neonatal respiratory distress syndrome, neonatal sepsis, necrotising enterocolitis, and admission to neonatal intensive care unit compared with controls.
CONCLUSION: Vaginal progesterone should be considered the preventative treatment of choice for women with singleton pregnancy identified to be at risk of spontaneous preterm birth because of a history of spontaneous preterm birth or short cervical length. Future randomised controlled trials should use vaginal progesterone as a comparator to identify better treatments or combination treatments.
SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42020169006.
参考来源
- Care A, Nevitt SJ, Medley N, et al. Interventions to prevent spontaneous preterm birth in women with singleton pregnancy who are at high risk: systematic review and network meta-analysis. BMJ. 2022. PMID: 35168930. doi:10.1136/bmj-2021-064547
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。